5-fluorouracil

5-Fluorouracil (5-FU) is a uracil analog and inhibitor of DNA synthesis, exhibiting antitumor activity by affecting pyrimidine synthesis through thymidylate synthase inhibition; it induces apoptosis and autophagy.

Levoleucovorin Calcium (CL307782), a calcium salt of the folinic acid, is used in cancer chemotherapy as an adjuvant.

Carmofur (HCFU) is a highly potent acid ceramidase inhibitor, used in the treatment of breast and colorectal cancer. Carmofur has been known to induce leukoencephalopathy.

Fosifloxuridine nafalbenamide (NUC 3373), a pyrimidine nucleotide analogue, is a Thymidylate synthase inhibitor. NUC-3373 has anticancer activity. NUC-3373 is a ProTide transformation of 5-FU that generates much higher concentrations of FUDR-MP in patients' cells.

Eniluracil (GW776C85) is an orally activedihydropyrimidine dehydrogenase (DPD) inhibitor,increases the oral bioavailability of 5-FU to 100%, facilitating uniform absorption and predictable toxicity.

1-(b-D-Xylofuranosyl)-5-fluorouracil is a nucleoside derivative, specifically a xylo-nucleoside and fluoro-modified nucleoside, characterized by a 5-modified pyrimidine nucleoside structure.

1-Acetyl-3-o-toluyl-5-fluorouracil is a potent antineoplastic agent.

5,6-dihydro-5-Fluorouracil (5-FUH2) is an inactive metabolite of 5-FU and can be used for the study of organismal metabolism.

5-Fluorouracil-13C,15N2 is intended for use as an internal standard for the quantification of 5-flurouracil by GC- or LC-MS. 5-Fluorouracil (T0984) is a pyrimidine analog that irreversibly inhibits thymidylate synthase, blocking the synthesis of thymidine which is required for DNA synthesis. Intracellular metabolites of 5-fluorouracil exert cytotoxic effects by either inhibiting thymidylate synthetase, or through incorporation into RNA and DNA, ultimately initiating apoptosis.

1,3-Dibenzyl-5-fluorouracil is a chemical inhibitor that suppresses the formation of osteoclasts, functioning by downregulating the signaling pathways of nuclear factor κB ligand receptor activator (Receptor activator of NF-κB ligand, RANKL) and macrophage colony-stimulating factor (M-CSF). This compound is used in the research of metabolic bone diseases.

5-Fluorouracil-D1 is the deuterated form of 5-Fluorouracil. 5-Fluorouracil (T0984) (5-FU) is a nucleoside antimetabolite, a uracil analog with potent antitumor properties. It interferes with pyrimidine synthesis by inhibiting thymidylate synthase, depleting the intracellular dTTP pool. 5-Fluorouracil (T0984) induces apoptosis and can be used as a chemosensitizer. Additionally, it inhibits the HIV virus and disrupts exosome-specific rRNA.

5-Fluorouracil-15N2 is a nitrogen-15 labeled form of 5-Fluorouracil (T0984) (5-FU), a uracil analog (nucleoside antimetabolite/analog) and potent antitumor agent. It hampers pyrimidine synthesis by inhibiting thymidylate synthase, depleting the intracellular dTTP pool, inducing apoptosis, acting as a chemotherapeutic sensitizer, inhibiting HIV, and damaging exosome-specific rRNA.

5-Fluorouracil (Standard) is a reference standard for research and analysis in studies involving 5-Fluorouracil. 5-Fluorouracil (5-FU) is a uracil analog, an inhibitor of DNA synthesis. 5-Fluorouracil has antitumor activity and affects pyrimidine synthesis through inhibition of thymidylate synthase. 5-Fluorouracil causes apoptosis and autophagy.

5-Fluorouracil-13C,15N2 (Standard) is a reference standard of 5-Fluorouracil-13C,15N2 intended for quantitative analysis, quality control, and related biochemical research applications. 5-Fluorouracil-13C,15N2 is intended for use as an internal standard for the quantification of 5-flurouracil by GC- or LC-MS. 5-Fluorouracil is a pyrimidine analog that irreversibly inhibits thymidylate synthase, blocking the synthesis of thymidine which is required for DNA synthesis. Intracellular metabolites of 5-fluorouracil exert cytotoxic effects by either inhibiting thymidylate synthetase, or through incorporation into RNA and DNA, ultimately initiating apoptosis.

5-Fluorouracil-15N2 (Standard) is a reference standard of 5-Fluorouracil-15N2 intended for quantitative analysis, quality control, and related biochemical research applications. 5-Fluorouracil-15N2 is a nitrogen-15 labeled form of 5-Fluorouracil (5-FU), a uracil analog (nucleoside antimetabolite/analog) and potent antitumor agent. It hampers pyrimidine synthesis by inhibiting thymidylate synthase, depleting the intracellular dTTP pool, inducing apoptosis, acting as a chemotherapeutic sensitizer, inhibiting HIV, and damaging exosome-specific rRNA.

5-Fluorouracil-1-yl acetic acid methyl ester is a PNA-related Derivative.

5-Fluorouracil-1-yl acetic acid is a PNA-related Derivative.

Floxuridine (FUDR) is an antimetabolite, floxuridine inhibits thymidylate synthase, resulting in disruption of DNA synthesis and cytotoxicity.

Emitefur (BOF-A 2) is an orally active and potent 5-fluorouracil derivative with anticancer and antitumor activity.Emitefur is used in advanced gastric cancer, breast cancer and metabolism-related diseases.

ZX-J-19J (N-(2,3-Diphenyl-6-quinoxalinyl)octanamide), an inhibitor of Cyclophilin J (CyPJ), demonstrates remarkable inhibition of tumor cell growth, comparable to cyclosporine A but much stronger than 5-fluorouracil.

5-Fluorouridine is a metabolite of 5-fluorouracil that inhibits rRNA synthesis in human colon cancer cells and exhibits antitumor and antiviral activity. 5-Fluorouridine exerts a cytotoxic effect on the growth of L1210 cells, with an IC₅₀ value of 2 nM. 5-Fluorouridine binds to poly-A RNA and exhibits antiproliferative activity. 5-Fluorouridine can be used in studies of nucleic acid metabolism, cancer chemotherapy, and viral replication mechanisms.

Capecitabine (Capecitibine) is a fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites. As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells. FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand.

Doxifluridine (AMC 0101) is a fluoropyrimidine derivative and oral prodrug of the antineoplastic agent 5-fluorouracil (5-FU) with antitumor activity. Doxifluridine, designed to circumvent the rapid degradation of 5-FU by dihydropyrimidine dehydrogenase in the gut wall, is converted into 5-FU in the presence of pyrimidine nucleoside phosphorylase. 5-FU interferes with DNA synthesis and subsequent cell division by reducing normal thymidine production and interferes with RNA transcription by competing with uridine triphosphate for incorporation into the RNA strand.

Uridine triacetate (RG 2133 triacetate) (Tri-O-acetyl uridine), an orally active prodrug of uridine, is efficiently absorbed in the gut and swiftly deacetylated in the circulation to release free uridine. It is utilized in the research of 5-fluorouracil (5-FU) and capecitabine toxicity, particularly targeting early-onset cardiac or central nervous system (CNS) complications.